| CatalogCode: | NB100-2056 |
| ProductName: | TRAIL Antibody |
| Product Description: | Rabbit Polyclonal anti-TRAIL |
| Clonality: | Polyclonal |
| Immunogen: | Synthetic peptide (Human) (C terminal). |
| CrossReactivity: | Cross-reacts with Human, Rat and Mouse. Not yet tested in other species. |
| Packaging: | 1 ml Rabbit antisera. |
| Uses: | optimal dilutions should be determined by the user. |
| Localization: | Type II membrane protein |
| Background: | Apoptosis or programmed cell death is induced in cells by a group of death domain containing receptors. Binding of ligand to these receptors sends signals that activate members of the caspase family of proteases. The signals ultimately cause degradation of chromosomal DNA by activating DNase. TRAIL (TNF related apoptosis induced ligand) or Apo 2L initiates apoptosis of tumor cells by binding to either of its receptors, DR4 or DR5. These receptors consist of an extracellular TRAIL binding domain and a cytoplasmic "death domain". In addition, two decoy receptors for TRAIL have also been identified. These receptors, designated DcR1 and DcR2, lack the death domain. Binding of TRAIL to either of these receptors, therefore, does not transmit the death signal. Thus, these receptors represent a novel way of regulating cell sensitivity to a pro-apoptotic cytokine at the cell surface. TRAIL is expressed predominantly in spleen, lung, and prostate but also in many other tissues. |
| Storage: | Store at 4C. Do not freeze. |
| Isotype: | IgG |
| Host_Name: | Rabbit |
| Buffer: | Constituents: 0.2% Gelatin, PBS |
| ListPrice: | 325 |
| AppSummary: | IP, WB, IHC-Fr |
| SpeciesSummary: | Hu, Mu, Rt |
| ALTnames: | anti-Apo 2 ligand antibody, anti-Apo 2L antibody, anti-APO2L antibody, anti-CD253 antibody, anti-TL2 antibody, anti-TNF Related Apoptosis Inducing Ligand antibody, anti-TNFSF10 antibody, anti-TRAIL antibody, anti-TRAIL PEN antibody,, anti- Tumor Necrosis Factor (ligand) Superfamily Member 10 antibody |
| ProteinTarget: | Trail |
| PackageSize: | 1 ml |
| GeneralRef: | Wajant H et al. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7:449-59 (2002). Nagane M et al. The potential of TRAIL for cancer chemotherapy. Apoptosis 6:191-7 (2001). Phillips TA et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol 162:6053-9 (1999). Gura T How TRAIL kills cancer cells, but not normal cells. Science 277:768 (1997). Pitti RM et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-90 (1996). |
|